Entecavir for the treatment of chronic hepatitis B

[Guest guest]

Future Drugs Journal

Expert Review of Anti-infective Therapy

Drug Profile

Entecavir for the treatment of chronic hepatitis B

Tim Shaw and Locarnini

Expert Review of Anti-infective Therapy 2(6),853-871 (2004)

Chronic infection with the hepatitis B virus remains a serious and

life-threatening disease for approximately 5% of the world's population,

despite the availability of effective vaccines. Although prognoses can be

improved by chemotherapy, treatment options are limited and none has been

consistently successful. Interferon-a, the longest established therapy, has

limited efficacy, is slow-acting and frequently causes adverse effects.

Newer drugs comprise of mainly nucleoside and nucleotide analogs. The two

that are currently approved, lamivudine and adefovir dipivoxil, are well

tolerated; both produce rapid and dramatic responses, but their effects may

not be sustainable in the long-term due to the emergence of resistant virus.

Development of resistance to lamivudine is approximately ten-times more

frequent than development of resistance to adefovir dipivoxil (~60 and 6%,

respectively) during the first 3 years of therapy. Entecavir, a carbocyclic

deoxyguanosine analog that is active against both lamivudine- and adefovir

dipivoxil-resistant HBV, is in the vanguard of new antihepatitis B virus

drugs that have progressed to Phase III clinical trials. It is the most

potent antihepatitis B virus agent discovered to date.

http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm & refid=703 & specid\

=45 & id=061C33FC2A7F39888525689900589BFE & newsid=8525697700573E1885256F5D006AC942 & \

prevpage=0 & u=GOTO//www.future-drugs.com/summery.asp?submit=txt1 & articleid=1865 & p\

ublicationid=7 & ref=

[Guest guest]

Future Drugs Journal

Expert Review of Anti-infective Therapy

Drug Profile

Entecavir for the treatment of chronic hepatitis B

Tim Shaw and Locarnini

Expert Review of Anti-infective Therapy 2(6),853-871 (2004)

Chronic infection with the hepatitis B virus remains a serious and

life-threatening disease for approximately 5% of the world's population,

despite the availability of effective vaccines. Although prognoses can be

improved by chemotherapy, treatment options are limited and none has been

consistently successful. Interferon-a, the longest established therapy, has

limited efficacy, is slow-acting and frequently causes adverse effects.

Newer drugs comprise of mainly nucleoside and nucleotide analogs. The two

that are currently approved, lamivudine and adefovir dipivoxil, are well

tolerated; both produce rapid and dramatic responses, but their effects may

not be sustainable in the long-term due to the emergence of resistant virus.

Development of resistance to lamivudine is approximately ten-times more

frequent than development of resistance to adefovir dipivoxil (~60 and 6%,

respectively) during the first 3 years of therapy. Entecavir, a carbocyclic

deoxyguanosine analog that is active against both lamivudine- and adefovir

dipivoxil-resistant HBV, is in the vanguard of new antihepatitis B virus

drugs that have progressed to Phase III clinical trials. It is the most

potent antihepatitis B virus agent discovered to date.

http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm & refid=703 & specid\

=45 & id=061C33FC2A7F39888525689900589BFE & newsid=8525697700573E1885256F5D006AC942 & \

prevpage=0 & u=GOTO//www.future-drugs.com/summery.asp?submit=txt1 & articleid=1865 & p\

ublicationid=7 & ref=

[Guest guest]

Future Drugs Journal

Expert Review of Anti-infective Therapy

Drug Profile

Entecavir for the treatment of chronic hepatitis B

Tim Shaw and Locarnini

Expert Review of Anti-infective Therapy 2(6),853-871 (2004)

Chronic infection with the hepatitis B virus remains a serious and

life-threatening disease for approximately 5% of the world's population,

despite the availability of effective vaccines. Although prognoses can be

improved by chemotherapy, treatment options are limited and none has been

consistently successful. Interferon-a, the longest established therapy, has

limited efficacy, is slow-acting and frequently causes adverse effects.

Newer drugs comprise of mainly nucleoside and nucleotide analogs. The two

that are currently approved, lamivudine and adefovir dipivoxil, are well

tolerated; both produce rapid and dramatic responses, but their effects may

not be sustainable in the long-term due to the emergence of resistant virus.

Development of resistance to lamivudine is approximately ten-times more

frequent than development of resistance to adefovir dipivoxil (~60 and 6%,

respectively) during the first 3 years of therapy. Entecavir, a carbocyclic

deoxyguanosine analog that is active against both lamivudine- and adefovir

dipivoxil-resistant HBV, is in the vanguard of new antihepatitis B virus

drugs that have progressed to Phase III clinical trials. It is the most

potent antihepatitis B virus agent discovered to date.

http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm & refid=703 & specid\

=45 & id=061C33FC2A7F39888525689900589BFE & newsid=8525697700573E1885256F5D006AC942 & \

prevpage=0 & u=GOTO//www.future-drugs.com/summery.asp?submit=txt1 & articleid=1865 & p\

ublicationid=7 & ref=

[Guest guest]

Future Drugs Journal

Expert Review of Anti-infective Therapy

Drug Profile

Entecavir for the treatment of chronic hepatitis B

Tim Shaw and Locarnini

Expert Review of Anti-infective Therapy 2(6),853-871 (2004)

Chronic infection with the hepatitis B virus remains a serious and

life-threatening disease for approximately 5% of the world's population,

despite the availability of effective vaccines. Although prognoses can be

improved by chemotherapy, treatment options are limited and none has been

consistently successful. Interferon-a, the longest established therapy, has

limited efficacy, is slow-acting and frequently causes adverse effects.

Newer drugs comprise of mainly nucleoside and nucleotide analogs. The two

that are currently approved, lamivudine and adefovir dipivoxil, are well

tolerated; both produce rapid and dramatic responses, but their effects may

not be sustainable in the long-term due to the emergence of resistant virus.

Development of resistance to lamivudine is approximately ten-times more

frequent than development of resistance to adefovir dipivoxil (~60 and 6%,

respectively) during the first 3 years of therapy. Entecavir, a carbocyclic

deoxyguanosine analog that is active against both lamivudine- and adefovir

dipivoxil-resistant HBV, is in the vanguard of new antihepatitis B virus

drugs that have progressed to Phase III clinical trials. It is the most

potent antihepatitis B virus agent discovered to date.

http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm & refid=703 & specid\

=45 & id=061C33FC2A7F39888525689900589BFE & newsid=8525697700573E1885256F5D006AC942 & \

prevpage=0 & u=GOTO//www.future-drugs.com/summery.asp?submit=txt1 & articleid=1865 & p\

ublicationid=7 & ref=